FIELD: medicine.
SUBSTANCE: dispase solution 2 mcl containing an enzyme in a dose of 0.03 U is introduced into rats' vitreous cavities. Signs of vitreoretinopathy are stated 6 weeks after the enzyme introduction.
EFFECT: method enables creating the adequate model of the disease.
3 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR SIMULATING PROLIFERATIVE VITREORETINOPATHY IN RATS | 2014 |
|
RU2563368C1 |
METHOD FOR SIMULATING PROLIFERATIVE VITREORETINOPATHY | 2014 |
|
RU2568368C1 |
METHOD FOR MODELING PROLIFERATIVE VITRORETINOPATHY | 1998 |
|
RU2161335C2 |
METHOD FOR THE TREATMENT OF PROLIFERATIVE PROCESSES OF THE POSTERIOR SEGMENT OF THE EYE | 2018 |
|
RU2684927C1 |
METHOD FOR TREATING PROLIFERATIVE VITREORETINOPATHY USING LIPOSOME-ASSOCIATED MELPHALAN IN AN EXPERIMENT | 2021 |
|
RU2772520C1 |
METHOD FOR TREATING PROLIFERATIVE VITREORETINOPATHY | 2005 |
|
RU2284812C1 |
METHOD FOR PREVENTING PROLIFERATIVE VITREORETINOPATHY | 1999 |
|
RU2175223C2 |
SURGICAL METHOD FOR TREATING THE CASES OF REGMATOGENIC RETINAL DETACHMENT COMBINED WITH POSTERIOR DETACHMENT OF VITREOUS BODY | 2000 |
|
RU2203001C2 |
TREATMENT METHOD OF AGE-RELATED MACULAR DEGENERATION | 2008 |
|
RU2368359C1 |
METHOD FOR TREATING THE CASES OF AMOTIO RETINAE AGGRAVATED BY PROLIFERATIVE VITREORETINOPATHY | 2001 |
|
RU2199298C1 |
Authors
Dates
2015-08-10—Published
2014-01-31—Filed